Asarfi Hospital Ltd

Asarfi Hospital Limited — Trading Window closed from October 01, 2026 until 48 hours after the declaration of the Unaudited Financial Results for the quarter & half year ended September 30, 2026

Voting results submission

• Consolidated voting results for the 21st AGM and Scrutinizer report submitted under Regulation 44.
• Results cover remote e-voting and AGM voting; will be on the company website.

AGM Details

• AGM held 18 Sep 2026, starting 12:00 PM, in-person at registered office.
• Concluded 2:00 PM on the same day.
• Remote e-voting window: 15 Sep 2026 10:00 AM to 17 Sep 2026 5:00 PM.
• Present: 16 members and 6 proxies/authorised representatives.
• Chairman presided over proceedings.

Key Resolutions & Outcomes

• Adoption of audited standalone and consolidated financial statements; ordinary resolution; approved.
• Re-appointment by rotation of director; ordinary resolution; approved.
• Migration to BSE Main Board and NSE listing; ordinary resolution; approved.

Key approvals

• Directors' Report for year ended March 31, 2026 approved.
• Re-appointment of Mr. Gopal Singh as Director approved.

AGM and related actions

• 21st AGM scheduled for September 18, 2026 at 12:00 Noon.
• Books closed from September 5 to 18, 2026.
• Voting cutoff fixed for September 11, 2026.
• AGM Notice approved for circulation.
• Remote e-voting facilities to be provided by NSDL and Cameo.
• Scrutinizer appointed: CS Sourav Mall (A67274).

Governance and strategic actions

• Cost Auditor appointed: Ashutosh Kumar Sinha & Co for FY 2026-27.
• Migration to BSE Main Board and NSE listing approved in principle.
• Harendra Singh appointed Authorised Signatory for bidding documents.

Meeting Details

• Date: 25 August 2026.
• Time: 11:00 A.M.
• Venue: Registered Office, Asarfi Hospital Limited, Baramuri Bishunpur Polytechnic, Dhanbad, Jharkhand 828130.

Key Agenda Items

• To consider and approve Directors’ Report for the financial year ended 31 March 2026.
• Re-appointment of director retiring by rotation: Mr. Gopal Singh (DIN: 01608342) offered for re-appointment.
• Fix date, time and venue of the 21st AGM: 18 September 2026 at 12:00 Noon.
• Approve Book Closure/Record Date for AGM: 5 September 2026 to 18 September 2026.
• Appoint Cost Auditor for FY 2026-27: M/s Ashutosh Kumar Sinha & Co.
• Approve the AGM Notice along with Directors’ Report and documents.
• Discuss migration from BSE SME to BSE Main Board and NSE listing.

Publication of results

• Unaudited standalone and consolidated results for the quarter ended June 30, 2026 disclosed.
• Audit Committee approved the results; Board approval dated August 7, 2026.
• Newspaper advertisements published August 8, 2026 in The Times of India (Ranchi), Hindustan and Dainik Jagran.

Key metrics and outlook

• Revenue from operations and total income disclosed for both standalone and consolidated.
• FY27 revenue guidance: Rs 4,734 lakhs with EBITDA margin of 20% and PAT margin of 9%.
• Earnings per share information disclosed in the results.

Regulatory filing

• Results filed with stock exchanges as per regulatory requirements.

Financial highlights

• Standalone Q1 FY27 revenue ₹4,734.47 Lakhs; YoY growth 33%; EBITDA margin 20%; PAT margin 9%.
• Consolidated Q1 FY27 revenue ₹4,753.41 Lakhs; PAT ₹426.72 Lakhs; Basic EPS ₹2.17.
• IPD revenue up 31% YoY; OPD up 44% YoY; ARPOB ₹23,498 and ₹31,892 for Super-Specialty and Cancer.
• Unaudited results approved by Board on 07-Aug-2026; Audit Committee recommendations reported.

Business overview

• Two-hospital group in Dhanbad with 350 beds across Super-Specialty and Cancer Care.
• 2024: Cancer Institute established; 2025 MoU for Jharkhand’s first multi-organ transplant unit.
• Migrating from BSE SME to Main Board, subject to regulatory approvals.
• Capex upgrades include Cath Lab, Varian True Beam, and GE SPECT Gamma Camera.

Operational highlights

• Standalone Q1'FY27 revenue ₹4,734 Lakhs; YoY growth 32.8%.
• Standalone EBITDA ₹942 Lakhs; margin 19.9%.
• Standalone PAT ₹427 Lakhs; margin 9.0%.
• ARPOB for Super-Specialty: ₹23,498; Occupancy 59%.
• Consolidated revenue ₹4,753 Lakhs; EBITDA ₹946 Lakhs; PAT ₹427 Lakhs.
• Consolidated EBITDA margin 19.9%; PAT margin 9.0%.

Financial performance

• Standalone revenue growth supports expansion plans; margin discipline maintained.
• Consolidated metrics track Standalone performance with similar margins.

Capital structure & liquidity

• Migration to Main Board planned, subject to regulatory approvals.
• Net Debt/Equity 0.46x; ROCE 17.06% as of June 2026.
• Market cap ₹425 Cr; shares outstanding 1,96,77,300.

Strategic priorities & outlook

• MoU with Gleneagles, Chennai for Jharkhand's first multi-organ transplant unit.
• Upgraded Cath Lab with Philips Azurion 5 M12; IVUS added.
• GE Dual-Detector SPECT Gamma Camera installed; nuclear imaging strengthened.
• Expansion into Godda, Sahibganj, Pakur to widen regional network.

Governance & leadership

• Promoter MD: Udai Pratap Singh; CFO: Harendra Singh.
• Executive Directors: Madhuri Singh and Gopal Singh; Non-Executive Director Sukanti Kumar Das.

Financial results approved

• Board approved unaudited standalone and consolidated results for the quarter ended 30 June 2026.

Audit reports

• Limited Review Reports on standalone and consolidated results issued by the statutory auditors.

Key financial metrics

• Standalone quarterly revenue 4,793.73 Lakhs; PAT 426.84 Lakhs; EPS 2.17.
• Consolidated quarterly revenue 4,810.00 Lakhs; PAT 426.72 Lakhs; EPS 2.17.

Financial statements filed

• Balance sheets and cash flow statements for the quarter filed (standalone and consolidated).

Board meeting details

• Board meeting held on 7 August 2026.

Meeting Details

• 7 August 2026, 03:00 PM, at the Registered Office, Asarfi Hospital Limited, Dhanbad.

Key Agenda Items

• To ascertain quorum and call the meeting to order.
• To grant leave of absence to Directors, if any.
• To confirm minutes of the previous board meeting.
• To consider and approve unaudited financial results for quarter ended 30 June 2026 with Limited Review.
• To authorize filing of the results with stock exchanges and statutory authorities.